News headlines about Arbutus Biopharma (NASDAQ:ABUS) have been trending somewhat positive on Wednesday, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arbutus Biopharma earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 43.922860567574 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Accern’s analysis:
- Arbutus Biopharma Corporation (ABUS) stock RSI moves to 37.69 – Nasdaq Chronicle (nasdaqchronicle.com)
- Wedbush Downgrades Arbutus Biopharma (ABUS) to Neutral Citing limited Upside in 2018 – StreetInsider.com (streetinsider.com)
- Wedbush softens view on Arbutus on extended timeline for HBV candidates (seekingalpha.com)
- Wedbush Projects Limited Upside For Arbutus Shares This Year, Moves To Sidelines (finance.yahoo.com)
- Arbutus Biopharma (ABUS) Earns Buy Rating from Analysts at Chardan Capital (americanbankingnews.com)
ABUS has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub downgraded shares of Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 14th. ValuEngine downgraded shares of Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 15th. Chardan Capital reaffirmed a “buy” rating on shares of Arbutus Biopharma in a research note on Tuesday, January 16th. Finally, B. Riley initiated coverage on shares of Arbutus Biopharma in a research note on Friday, January 5th. They issued a “buy” rating and a $10.00 target price on the stock. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. Arbutus Biopharma has an average rating of “Hold” and an average target price of $12.38.
Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.51). Arbutus Biopharma had a negative net margin of 796.23% and a negative return on equity of 55.28%. The business had revenue of $2.50 million for the quarter, compared to the consensus estimate of $0.70 million. sell-side analysts forecast that Arbutus Biopharma will post -1.67 earnings per share for the current year.
About Arbutus Biopharma
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.